CD8A and neoplasm: The hallmark of tumor vaccines is to prime rare, tumor-specific CD8+ T cells from the naïve repertoire and expanding them into large effector pools capable of mediating cytotoxic activity, e.g., an in vitro ≥1000-fold expansion in two months [68,69,70].